Gates Foundation backs CureVac with $52m, Hopp invests $24m
This article was originally published in Scrip
Executive Summary
The Bill & Melinda Gates Foundation made its largest-ever equity investment in a biotechnology company when it committed $52m to the continued development of Tubingen, Germany-based CureVac's novel vaccines and construction of manufacturing facilities.
You may also be interested in...
CEPI Global Vaccines Launch May Augur Creation Of Credible Davos Deal
If in five years' time the newly launched CEPI coalition successfully produces DNA and RNA-based vaccines for use against future epidemics, then the high-profile Davos forum will really have something to crow about.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.